PRESS DIGEST- Financial Times - Dec 23

Headlines - Merck antiviral trial shows promising impact on COVID recovery time - TikTok admits to tracking FT journalist - Cinema chain AMC tumbles on plan to rework shares - Amazon hit by ECJ ruling on online sale of counterfeit goods - German regulator rebukes Standard Chartered over European operations Overview - Molnupiravir, the antiviral pill developed by Merck & Co to treat COVID-19, speeded up patients' recovery but failed to reduce risks of hospitalisation and death, full results of an extensive UK clinical trial showed.

The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines

- Merck antiviral trial shows promising impact on COVID recovery time - TikTok admits to tracking FT journalist

- Cinema chain AMC tumbles on plan to rework shares - Amazon hit by ECJ ruling on online sale of counterfeit goods

- German regulator rebukes Standard Chartered over European operations Overview

- Molnupiravir, the antiviral pill developed by Merck & Co to treat COVID-19, speeded up patients' recovery but failed to reduce risks of hospitalisation and death, full results of an extensive UK clinical trial showed. - ByteDance's TikTok has admitted it inappropriately obtained the data of users, including a Financial Times journalist, in order to analyse their location as part of an internal leaks investigation.

- AMC Entertainment Holdings said on Thursday it would raise $110 million in new equity capital through the sale of its preferred stock and proposed a reverse stock split. - Online retailer Amazon.com Inc may be deemed responsible for advertising of counterfeit Christian Louboutin shoes which found its way to its platform, Europe's top court said in a preliminary ruling on Thursday

- The German financial regulator BaFin said on Thursday that it had ordered the local operations of Standard Chartered to hold more capital, citing organisational flaws. (Compiled by Bengaluru newsroom)